Albany Molecular Res (AMRI) 14.59 $AMRI
AMRI CEO to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Mon May 23, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2
AMRI: 14.59 (-0.28)
AMRI Clarifies 2016 Revenue Guidance
PR Newswire - Tue May 10, 9:28AM CDT
AMRI (NASDAQ: AMRI) clarified its 2016 revenue guidance, following the company's first quarter earnings conference call held earlier this morning.
AMRI: 14.59 (-0.28)
Albany Molecular Research posts 1Q loss
Automated Insights - Tue May 10, 6:53AM CDT
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Tuesday reported a loss of $10.1 million in its first quarter.
AMRI: 14.59 (-0.28)
AMRI Announces First Quarter 2016 Results
PR Newswire - Tue May 10, 6:35AM CDT
AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2016 and provided an update to its outlook for 2016.
AMRI: 14.59 (-0.28)
AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance
PR Newswire - Mon May 09, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing.
AMRI: 14.59 (-0.28)
AMRI to Acquire Euticals in a Strategic Transaction That Expands its API Development and Manufacturing Business
PR Newswire Europe - Thu May 05, 6:50AM CDT
Enters definitive agreement to acquire Euticals for $358 million in stock, cash and a seller note -- Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry -- Significantly expands AMRI's presence in the European community -- Transaction expected to be accretive to AMRI's 2016 non-GAAP diluted EPS -- AMRI's 2017 pro forma revenue expected to exceed $750 million, with 2017 adjusted EBITDA margins of 20% AMRI today announced that it has signed a definitive agreement to acquire all outstanding shares of Prime European Therapeuticals S.p.A., also known as "Euticals", in a transaction valued at approximately $358 million (EUR 315 million), consisting of shares of AMRI common stock, cash, and a seller note.
AMRI: 14.59 (-0.28)
Rigaku Oxford Diffraction (ROD) is new provider of single crystal instrumentation to SSCI
PRWeb - Wed Apr 20, 3:07AM CDT
SSCI, a Division of Albany Molecular Research, located in West Lafayette, Indiana USA, and a leader and innovator in the field of cGMP solid state chemistry research and analytical services has taken delivery of Rigaku Oxford Diffraction SuperNova single crystal diffractometer. This acquisition expands the in-house capabilities of SSCI to include single crystal analysis, a technique that is of increasing importance in the field of structural characterization of pharmaceutical-related chemicals.
AMRI: 14.59 (-0.28)
AMRI Announces Filing of Annual Report on Form 10K
PR Newswire - Wed Mar 30, 6:11AM CDT
AMRI (NASDAQ: AMRI) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2015. A copy of the Annual Report on Form 10-K is available to be viewed or downloaded within the Investor Relations section of the Company's website at www.amriglobal.com.
AMRI: 14.59 (-0.28)
25.1% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Thu Mar 24, 12:41PM CDT
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 3 months, Albany Molecular Research has returned 25.06% as of today's recent price of $13.98.
AMRI: 14.59 (-0.28)
Shares of AMRI Down 16.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 9:46AM CST
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 2 months, Albany Molecular Research has returned 16.16% as of today's recent price of $15.64.
AMRI: 14.59 (-0.28)
Albany Molecular Research Shares Down 18.8% Since SmarTrend's Sell Call (AMRI)
Comtex SmarTrend(R) - Wed Feb 10, 9:49AM CST
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 1 month, Albany Molecular Research has returned 18.79% as of today's recent price of $15.15.
AMRI: 14.59 (-0.28)
AMRI to Announce Fourth Quarter and Full Year 2015 Results
PR Newswire - Tue Feb 09, 7:00AM CST
AMRI (NASDAQ: AMRI) today announced it will issue fourth quarter and full year 2015 financial results before the opening of the market on Wednesday, February 17, 2016. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 14.59 (-0.28)
AMRI names Anthony J. Maddaluna to board
M2 - Fri Feb 05, 3:01AM CST
Research & manufacturing company AMRI (NASDAQ:AMRI) reported on Thursday the addition of Anthony J. Maddaluna to its board of directors with immediate effect.
AMRI: 14.59 (-0.28)
AMRI Appoints Anthony J. Maddaluna to Board of Directors
PR Newswire - Thu Feb 04, 3:05PM CST
AMRI (NASDAQ: AMRI) today announced that Anthony J. Maddaluna, Executive Vice President of Pfizer Inc. and President of Pfizer Global Supply, has been elected to the AMRI Board of Directors, effective as of February 4, 2016. In addition, the Company announced that Mr. Gabe Leung, a director and member of the audit committee since 2010, has retired from the AMRI Board of Directors in order to devote further time and attention to his other business ventures.
PFE: 35.29 (-0.02), AMRI: 14.59 (-0.28)
AMRI appoints Dawn M. Von Rohr as senior VP of Active Pharmaceutical Ingredients API
M2 - Thu Jan 21, 4:06AM CST
Research and manufacturing company AMRI (NASDAQ:AMRI) reported on Wednesday that it has elected Dawn M. Von Rohr as senior vice president of its Active Pharmaceutical Ingredients (API) business.
AMRI: 14.59 (-0.28)
AMRI Announces Executive Hire to Lead Active Pharmaceutical Ingredients Business
PR Newswire - Wed Jan 20, 7:45AM CST
AMRI (NASDAQ: AMRI) announced today that Dawn M. Von Rohr, will join AMRI as Sr. Vice President, API, effective January 25, 2016. Ms. Von Rohr will report to George Svokos, Chief Operating Officer, and will be a member of the executive team led by President and Chief Executive Officer, William Marth. Ms. Von Rohr will have responsibility for setting and implementing the strategic direction for AMRI's growing Active Pharmaceutical Ingredient (API) business unit and for achieving the financial results of that business, AMRI's largest business unit.
AMRI: 14.59 (-0.28)
AMRI and NYCNMR Form Collaborative Agreement
PR Newswire - Thu Jan 14, 7:00AM CST
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that it has signed a collaboration agreement with the New York Center for Nanomedicine Research (NYCNMR) to co-market their nanotechnology services to global pharmaceutical and biotechnology clients.
AMRI: 14.59 (-0.28)
AMRI Announces 3-Year Extension of Insourcing Contract
PR Newswire - Tue Jan 12, 6:00AM CST
AMRI (NASDAQ: AMRI) is pleased to announce the extension of a key insourcing relationship with a major pharmaceutical company designed to accelerate their chemistry and drug discovery efforts. The original insourcing collaboration, which commenced in 2011, is being extended significantly beyond its original termination date of December 2018 to December 31, 2021.
AMRI: 14.59 (-0.28)
AMRI CEO to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Mon May 23, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2
AMRI: 14.59 (-0.28)
AMRI Clarifies 2016 Revenue Guidance
PR Newswire - Tue May 10, 9:28AM CDT
AMRI (NASDAQ: AMRI) clarified its 2016 revenue guidance, following the company's first quarter earnings conference call held earlier this morning.
AMRI: 14.59 (-0.28)
Albany Molecular Research posts 1Q loss
Automated Insights - Tue May 10, 6:53AM CDT
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Tuesday reported a loss of $10.1 million in its first quarter.
AMRI: 14.59 (-0.28)
AMRI Announces First Quarter 2016 Results
PR Newswire - Tue May 10, 6:35AM CDT
AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2016 and provided an update to its outlook for 2016.
AMRI: 14.59 (-0.28)
AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance
PR Newswire - Mon May 09, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing.
AMRI: 14.59 (-0.28)
AMRI to Acquire Euticals in a Strategic Transaction That Expands its API Development and Manufacturing Business
PR Newswire Europe - Thu May 05, 6:50AM CDT
Enters definitive agreement to acquire Euticals for $358 million in stock, cash and a seller note -- Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry -- Significantly expands AMRI's presence in the European community -- Transaction expected to be accretive to AMRI's 2016 non-GAAP diluted EPS -- AMRI's 2017 pro forma revenue expected to exceed $750 million, with 2017 adjusted EBITDA margins of 20% AMRI today announced that it has signed a definitive agreement to acquire all outstanding shares of Prime European Therapeuticals S.p.A., also known as "Euticals", in a transaction valued at approximately $358 million (EUR 315 million), consisting of shares of AMRI common stock, cash, and a seller note.
AMRI: 14.59 (-0.28)
Rigaku Oxford Diffraction (ROD) is new provider of single crystal instrumentation to SSCI
PRWeb - Wed Apr 20, 3:07AM CDT
SSCI, a Division of Albany Molecular Research, located in West Lafayette, Indiana USA, and a leader and innovator in the field of cGMP solid state chemistry research and analytical services has taken delivery of Rigaku Oxford Diffraction SuperNova single crystal diffractometer. This acquisition expands the in-house capabilities of SSCI to include single crystal analysis, a technique that is of increasing importance in the field of structural characterization of pharmaceutical-related chemicals.
AMRI: 14.59 (-0.28)
AMRI Announces Filing of Annual Report on Form 10K
PR Newswire - Wed Mar 30, 6:11AM CDT
AMRI (NASDAQ: AMRI) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2015. A copy of the Annual Report on Form 10-K is available to be viewed or downloaded within the Investor Relations section of the Company's website at www.amriglobal.com.
AMRI: 14.59 (-0.28)
25.1% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Thu Mar 24, 12:41PM CDT
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 3 months, Albany Molecular Research has returned 25.06% as of today's recent price of $13.98.
AMRI: 14.59 (-0.28)
Shares of AMRI Down 16.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 9:46AM CST
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 2 months, Albany Molecular Research has returned 16.16% as of today's recent price of $15.64.
AMRI: 14.59 (-0.28)
Albany Molecular Research Shares Down 18.8% Since SmarTrend's Sell Call (AMRI)
Comtex SmarTrend(R) - Wed Feb 10, 9:49AM CST
SmarTrend identified a Downtrend for Albany Molecular Research (NASDAQ:AMRI) on January 6th, 2016 at $18.66. In approximately 1 month, Albany Molecular Research has returned 18.79% as of today's recent price of $15.15.
AMRI: 14.59 (-0.28)
AMRI to Announce Fourth Quarter and Full Year 2015 Results
PR Newswire - Tue Feb 09, 7:00AM CST
AMRI (NASDAQ: AMRI) today announced it will issue fourth quarter and full year 2015 financial results before the opening of the market on Wednesday, February 17, 2016. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 14.59 (-0.28)
AMRI names Anthony J. Maddaluna to board
M2 - Fri Feb 05, 3:01AM CST
Research & manufacturing company AMRI (NASDAQ:AMRI) reported on Thursday the addition of Anthony J. Maddaluna to its board of directors with immediate effect.
AMRI: 14.59 (-0.28)
AMRI Appoints Anthony J. Maddaluna to Board of Directors
PR Newswire - Thu Feb 04, 3:05PM CST
AMRI (NASDAQ: AMRI) today announced that Anthony J. Maddaluna, Executive Vice President of Pfizer Inc. and President of Pfizer Global Supply, has been elected to the AMRI Board of Directors, effective as of February 4, 2016. In addition, the Company announced that Mr. Gabe Leung, a director and member of the audit committee since 2010, has retired from the AMRI Board of Directors in order to devote further time and attention to his other business ventures.
PFE: 35.29 (-0.02), AMRI: 14.59 (-0.28)
AMRI appoints Dawn M. Von Rohr as senior VP of Active Pharmaceutical Ingredients API
M2 - Thu Jan 21, 4:06AM CST
Research and manufacturing company AMRI (NASDAQ:AMRI) reported on Wednesday that it has elected Dawn M. Von Rohr as senior vice president of its Active Pharmaceutical Ingredients (API) business.
AMRI: 14.59 (-0.28)
AMRI Announces Executive Hire to Lead Active Pharmaceutical Ingredients Business
PR Newswire - Wed Jan 20, 7:45AM CST
AMRI (NASDAQ: AMRI) announced today that Dawn M. Von Rohr, will join AMRI as Sr. Vice President, API, effective January 25, 2016. Ms. Von Rohr will report to George Svokos, Chief Operating Officer, and will be a member of the executive team led by President and Chief Executive Officer, William Marth. Ms. Von Rohr will have responsibility for setting and implementing the strategic direction for AMRI's growing Active Pharmaceutical Ingredient (API) business unit and for achieving the financial results of that business, AMRI's largest business unit.
AMRI: 14.59 (-0.28)
AMRI and NYCNMR Form Collaborative Agreement
PR Newswire - Thu Jan 14, 7:00AM CST
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that it has signed a collaboration agreement with the New York Center for Nanomedicine Research (NYCNMR) to co-market their nanotechnology services to global pharmaceutical and biotechnology clients.
AMRI: 14.59 (-0.28)
AMRI Announces 3-Year Extension of Insourcing Contract
PR Newswire - Tue Jan 12, 6:00AM CST
AMRI (NASDAQ: AMRI) is pleased to announce the extension of a key insourcing relationship with a major pharmaceutical company designed to accelerate their chemistry and drug discovery efforts. The original insourcing collaboration, which commenced in 2011, is being extended significantly beyond its original termination date of December 2018 to December 31, 2021.
AMRI: 14.59 (-0.28)
